In summary, from the perspective of Chinese health care system, gene-guided icotinib therapy for newly diagnosed advanced NSCLC harboring EGFR mutations is a cost-effective alternative relative to chemotherapy containing pemetrexed and gefitinib, based on the higher efficacy and lower cost of icotinib treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.